CD19 and B-cell non-Hodgkin lymphoma: T cells expressing chimeric antigen receptors (CARs) targeting CD19, CD20, CD22 and CD30 were able to kill around 50% of different B cell lymphomas in cell culture, and have provided spectacular results in clinical trials, with 60% of B cell lymphoma and leukemia patients in complete remission after treatment (219–223).